A Multicenter, Randomized Controlled Trial for Green Therapy for Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC)

Dongfang Hospital, Beijing University of Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•(1) Histologic or cytologic diagnosis of NSCLC and the 8th TNM system of lung cancer staging IIIb-IV based on IASLC;
•(2) One of five syndromes including deficiency of both qi and yin,qi deficiency of spleen and lung, deficiency of lung yin, stagnation of qi and blood stasis and phlegm-heat obstructing lung based on the TCM diagnosis and treatment of lung cancer (2017) issued by State Administration of Traditional Chinese Medicine of the People's Republic of China;
•(3) At least one lesion of diameter >2cm exsiting in the lung that was capable of cryoablation;
•(4) Eastern Cooperative Oncology Group (ECOG) performance status less than 2 points and life expectancy of at least 3 months;
•(5) Aged >=18 years;
•(6) Patients volunteer to participate, and sign the informed consent.

•(1) Cancer treatment including radiotherapy, chemotherapy, targeted therapy or immunotherapy within one month;
•(2) Symptomatic brain metastasis;
•(3) Poor control of infectious and radioactive inflammation around the target lesion or skin infection and ulceration at the puncture site;
•(4) Severe pulmonary fibrosis especially induced by drug;
•(5) Severe bleeding tendency, platelet less than 50×109/L and severe coagulation disorder;
•(6) Poor control of malignant pleural effusion in the ipsilateral of cryoablation;
•(7) Pregnancy or lactation, or severe dysfuction of liver, kidney, heart, lung and brain, or severe anemia, dehydration and metabolism disorders which cannot be corrected or improved in short-term , or severe systemic infection with high fever (T>38.5 degree C);
•(8) Antibody of HIV is positive, or other acquired/congenital immunity;
•(9) Organ transplantation;
•(10) Participating in other clinical trials within recent three months.

发起方

Dongfang Hospital, Beijing University of Chinese Medicine